Correlation Between Elevation Oncology and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Elevation Oncology and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elevation Oncology and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Elevation Oncology and Cue Biopharma, you can compare the effects of market volatilities on Elevation Oncology and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elevation Oncology with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elevation Oncology and Cue Biopharma.
Diversification Opportunities for Elevation Oncology and Cue Biopharma
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Elevation and Cue is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Elevation Oncology and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Elevation Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elevation Oncology are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Elevation Oncology i.e., Elevation Oncology and Cue Biopharma go up and down completely randomly.
Pair Corralation between Elevation Oncology and Cue Biopharma
Given the investment horizon of 90 days Elevation Oncology is expected to generate 0.7 times more return on investment than Cue Biopharma. However, Elevation Oncology is 1.43 times less risky than Cue Biopharma. It trades about 0.05 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.17 per unit of risk. If you would invest 60.00 in Elevation Oncology on August 31, 2024 and sell it today you would earn a total of 2.00 from holding Elevation Oncology or generate 3.33% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Elevation Oncology vs. Cue Biopharma
Performance |
| Timeline |
| Elevation Oncology |
| Cue Biopharma |
Elevation Oncology and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Elevation Oncology and Cue Biopharma
The main advantage of trading using opposite Elevation Oncology and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elevation Oncology position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.| Elevation Oncology vs. Cue Biopharma | Elevation Oncology vs. Tff Pharmaceuticals | Elevation Oncology vs. Eliem Therapeutics | Elevation Oncology vs. Inhibrx |
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |